口服盐酸特比萘芬与听力障碍相关性数据挖掘研究

口服盐酸特比萘芬与听力障碍相关性数据挖掘研究

李梅,曹玉莹,王丽伟

吉林大学公共卫生学院医学信息学系,130021,吉林大学公共卫生学院医学信息学系,130021,吉林大学公共卫生学院医学信息学系,130021

收稿日期:2015-12-17 修回日期:2015-12-17 出版日期:2016-02-25 发布日期:2016-01-25
基金资助:
吉林省教育厅“十二五”社会科学研究项目（项目编号：吉教科文合字[2014]第B020号）；吉林大学基本科研业务费项目（项目编号：2015QY014）

Data Mining of Association between Oral Terbinafine Hydrochloride and Hearing Impairment

李梅, and

School of Public Health,,

Received:2015-12-17 Revised:2015-12-17 Online:2016-02-25 Published:2016-01-25

摘要/Abstract

摘要： ［摘要］目的：检测口服盐酸特比萘芬引起听力障碍的药品不良反应信号。方法：AERS-DM是对美国不良反应报告系统AERS数据进行去重、标准化与知识聚合的不良反应数据库，本研究在AERS-DM中进行数据挖掘，计算不良反应信号比例报告比值比（proportional ADR reporting ratio，PRR）和报告比值比（reporting odds ratio，ROR）。PRR的判定标准为：当药物引起不良反应例数>3，PRR≥2，四格表χ2≥4，则提示生成不良反应信号。ROR的判定标准为：当ROR95%可信区间下限>1则提示生成不良反应信号。结果：检测到PRR和ROR不良反应信号。PRR=3.77>2，χ2=20.39>4，药物引起不良反应例数>3，提示生成不良反应信号；ROR=3.78，ROR的95%可信区间（2.03，7.03），下限>1，提示生成不良反应信号。结论：基于AERS-DM数据检测不良反应信号结果表明口服盐酸特比萘芬与听力障碍具有相关性。

Abstract: [Abstract]Objective： To detect the adverse event signal between oral terbinafine hydrochloride and hearing impairment. Methods： AERS-DM is a knowledge-aggregated database of the adverse events after de-duplicating， normalizing the FDA AERS data. This study used the method of proportional reporting ratio， reporting odds ratio for data mining. Using the PRR， a signal is detected if the number of co-occurrences is 3 or more and the PRR is 2 or more with an associated χ2 value of 4 or more. For the ROR， a signal is detected， if the lower limit of the 95% two-sided confidence interval exceeds 1. Results： The result shows adverse event signals PRR and ROR are detected. The PRR=3.77>2，χ2=20.39>4，the number of co-occurrences is more than 3， a signal is detected. The ROR=3.78， the 95% two-sided confidence interval is （2.03，7.03）， the lower limit exceeds 1， a signal is detected. Conclusion： The result shows there is association between oral terbinafine hydrochloride and hearing impairment in AERS-DM by detecting the adverse event signal.

李梅,曹玉莹,王丽伟. 口服盐酸特比萘芬与听力障碍相关性数据挖掘研究[J]. .

李梅, and. Data Mining of Association between Oral Terbinafine Hydrochloride and Hearing Impairment[J]. .

参考文献

[1] 萧月兴,何凤霞,陈莎. 盐酸特比萘芬的临床应用及不良反应研究进展[J]. 中国现代医生,2011,32:27-28 43.
[2] 陈新谦,金有豫,汤光.新编药物学[M]. 第17 版.北京:人民卫生出版社, 2011. 119
[3] 陶春. 耳毒性药物及药源性耳聋的预防[J]. 中外医疗,2011,15:188.
[4] 司继刚. 药源性耳聋防治研究进展[J]. 中国药物警戒,2013,12:730-733.
[5] Scholl J H G, van Puijenbroek E P. Hearing Impairment Associated with Oral Terbinafine Use[J]. Drug safety, 2012, 35(8): 685-691.
[6] Scholl J H G. Oral terbinafine use may be linked to hearing impairment[J]. Reactions, 2012, 1414: 11.
[7] Scholl J H G. First report of hearing impairment: 6 case reports[J]. Reactions, 2012, 1413: 4.
[8] 尚鹏辉,詹思延. 数据挖掘在药品不良反应信号检出和分析中的应用(上)——药物流行病学研究新方法系列讲座(二)[J]. 中国药物应用与监测,2009,02:121-123.
[9] 王丽伟,于跃,王伟.药品不良反应数据挖掘研究进展[J].中国医院药学杂志,2013,22:1880-1883.
[10] 刘花,杨世民,冯变玲. 美国药品不良反应监测体系简介及对我国的启示[J]. 中国执业药师,2013,04:39-43.
[11] Sakaeda T,Tamon A,Kadoyama K,Okuno Y. Data Mining of the Public Version of the FDA Adverse Event Reporting System. Int J Med Sci 2013,10(7):796-803.
[12] Wang L, Jiang G, Li D, et al. Standardizing adverse drug event reporting data.[J]. Journal of Biomedical Semantics, 2014, 5(1):36-36.
[13] Van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions[J]. Pharmacoepidemiol Drug Saf, 2002, 11(1): 3-10.
[14] Westerberg D P, Voyack M J. Onychomycosis: current trends in diagnosis and treatment[J]. American family physician, 2013, 88(11).
[15] de S? D C, Lamas A P B, Tosti A. Oral Therapy for Onychomycosis: An Evidence-Based Review[J]. American journal of clinical dermatology, 2014, 15(1): 17-36.
[16] 乔建军,张宏,石婧. 四种抗真菌药物治疗甲癣疗效比较的文献系统复习[J]. 中国皮肤性病学杂志,2005,07:419-421.
[17] 叶小飞,郭晓晶,赵璐,贺佳. 个例安全性报告规范(ICH E2B)简介及应用[J]. 中国药物警戒,2012,03:149-151.